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PER-1, an extended-spectrum -lactamase, has been reported only in Europe. We detected PER-1 in 53 of
97 acinetobacters in Korea, mainly in the sputum of intensive care unit patients. Pulsed-field gel electrophore-
sis analysis suggested that clonal spread had occurred. Only PCR reliably detected PER-1 producers. PER-1
producers may also exist in other Asian countries.
Multidrug-resistant Acinetobacter spp. and Pseudomonas
aeruginosa frequently cause serious nosocomial infections.
-Lactamase production is the most important mechanism of
-lactam resistance in gram-negative pathogens. PER-1 is an
extended-spectrum -lactamase which was first found in a P.
aeruginosa strain in France (7) and was then subsequently
detected in Acinetobacter spp. and P. aeruginosa in Turkey and
Italy (5, 12). PER-2 was reported in Salmonella enterica serovar
Typhimurium in Argentina (1). However, to our knowledge,
the PER-1 enzyme has not been reported in any other coun-
tries.
In a Korean hospital, cefepime-resistant acinetobacters in-
creased significantly from 29 to 47% of isolates, but those of P.
aeruginosa increased only slightly, from 14 to 17%, between
1991 (2) and 2000 (data not shown), which suggested the pres-
ence of PER-1-producing acinetobacters, as cefepime is stable
to AmpC but not to PER-1 -lactamase (5, 11). PER-1 pro-
duction has been found to be an independent indicator of poor
prognosis (13), but its detection by the double-disk synergy
(DDS) test is difficult (9).
The aim of this study was to determine the presence of
PER-1-producing strains of acinetobacter and P. aeruginosa in
Korea. The performance of the DDS test for the detection of
PER-1-producing isolates was also evaluated.
Strains of acinetobacter and P. aeruginosa were isolated in
2001 and 2002 from patients in two tertiary-care Korean hos-
pitals and were identified by conventional tests (3, 10) or by
using the ATB 32 GN system (bioMerieux, Marcy l’Etoile,
France). Antimicrobial susceptibilities were determined by the
disk diffusion and the agar dilution methods (6). DDS was
tested with cefotaxime, ceftazidime, aztreonam, cefepime, and
amoxicillin-clavulanate disks (Beckton Dickinson, Cockeys-
ville, Md.). Clavulanate (GlaxoSmithKline, Greenford, United
Kingdom) and tazobactam (Wyeth, Pearl River, N.Y.) were
used to add to cefepime disks.
blaPER-1 and blaPER-2 alleles were detected by PCR by using
previously reported primers (1, 9), heat-extracted templates,
and the mixture containing Taq DNA polymerase and dNTP
(Premix, Bioneer, Daejeon, Korea). The amplification condi-
tions used were 30 cycles of denaturation at 94°C for 40 s,
annealing at 50°C for 30 s, and extension at 72°C for 50 s. The
nucleotide sequences of both strands of the blaPER-1 allele
were analyzed with PCR products by the dideoxy-chain termi-
nation method with an ABI 3700 DNA sequencer (Perkin-
Elmer, Foster City, Calif.).
The isoelectric points of -lactamases were determined as
described previously (4). The transfer of blaPER-1 was tested by
plate mating with a rifampin-resistant Acinetobacter baumannii
recipient (YMC02/8/P534). Pulsed-field gel electrophoresis
(PFGE) of the SmaI-digested genomic DNA was performed
and analyzed as described previously (4). The DNA bands
separated by PFGE were transferred to a nylon membrane
and hybridized by using a digoxigenin-labeled blaPER-1 probe
(Roche Diagnostics, Mannheim, Germany).
In a preliminary study, blaPER-1 alleles were detected by
PCR in five DDS-positive acinetobacters from a hospital in a
southern region of Korea. The nucleotide sequences of blaPER-1
and the pI of the -lactamase in our isolates were identical to
those reported previously (5, 7, 8, 12).
The prevalence of blaPER-1-carrying acinetobacter was de-
termined in another hospital located approximately 300 km
north of the first hospital. Of the 97 consecutive isolates of
acinetobacter, 61 were resistant to ceftazidime and 53 (54.6%)
were positive for the blaPER-1 allele: 51 A. baumannii, 1 Acin-
etobacter genomospecies 3, and 1 unidentifiable Acinetobacter
spp.
blaPER-1 was not detected in 101 consecutive or in 181 cefta-
zidime-nonsusceptible P. aeruginosa isolates. blaPER-2 was not
detected in any of the acinetobacter or P. aeruginosa isolates
(data not shown).
blaPER-1 was detected in 46% of acinetobacter and 11% of P.
aeruginosa isolates in Turkey (12). It is interesting that blaPER-1-
positive acinetobacters were detected in Korea, which is geo-
graphically distanced from Europe. The resistance may also
exist in other Asian countries.
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All of the blaPER-1-positive acinetobacters were resistant to
ceftazidime, cefepime, cefotaxime, and aztreonam, but the re-
sistance rates of the blaPER-1-negative isolates to these drugs
and ampicillin-sulbactam were much lower (Table 1). The re-
sistance rates of blaPER-1-positive and -negative isolates were
64 and 30% to amikacin, 75 and 48% to gentamicin, 75 and
52% to tobramycin, 98 and 41% to trimethoprim-sulfamethox-
azole, and 83 and 39% to tetracycline, respectively (data not
shown). We anticipate difficulties in treating infections due
to PER-1-producing acinetobacters, as they are resistant to
all cephalosporins, including cefepime, and frequently to
aminoglycosides, trimethoprim-sulfamethoxazole, and tetra-
cycline.
Transfer of a blaPER-1-carrying the 81-MDa plasmid to Esch-
erichia coli was reported when plasmid pUZ8 existed in S.
enterica serovar Typhimurium (11). In our study, blaPER-1 was
transferred by conjugation to an A. baumannii recipient from 2
of 10 isolates tested, but repeated attempts failed to detect a
blaPER-1-carrying plasmid. SmaI-digested genomic DNA bands
of approximately 100 to 350 kb hybridized with the blaPER-1
probe, indicating the presence of the gene on the chromosome.
Fifty-three isolates of blaPER-1-positive acinetobacter showed
23 different PFGE patterns, indicating the presence of multiple
clones (Fig. 1), but 9 of 16 isolates with pattern A and 7 of 8
isolates with pattern O were from intensive care unit patients,
indicating clonal spread. Isolation of 39 (73.6%) strains from
sputum samples suggests these were the main source of trans-
mission.
DDS testing using ceftazidime, cefotaxime, or aztreonam
disks detected only 17 of the 53 blaPER-1 allele-positive isolates
when amoxicillin-clavulanate disks were placed 10 mm distant,
edge to edge. The use of 5-mm-distanced cefepime disks de-
tected 52 positive isolates, but the synergistic zones were small
and difficult to interpret. Slightly larger synergistic zones were
obtained when a cefepime disk and a 20-g clavulanate disk
were used (data not shown). These results indicated unreliabil-
ity of the DDS tests for the screening of PER-1-producing
acinetobacters.
Inhibition zone diameters by disks with cefepime alone and
cefepime plus clavulanate or tazobactam were compared, and
FIG. 1. Dendrogram of PFGE bands based on the coefficient of
Dice. Numbers of multiple isolates with the same band patterns are
shown in parentheses. Sixteen isolates had pattern A, and eight had
pattern O.
TABLE 1. Susceptibilities of blaPER-1-positive and -negative
isolates of acinetobacter
Antimicrobial
agent(s)
blaPER-1 test result
(no. of isolates
tested)
MIC (g/ml) Resist-
ance
(%)MIC range MIC90
d
Ampicillin-sulbactam Positive (53) 8–64 64 68
Negative (37) 0.5–64 32 27
Ceftazidime Positive (53) 128 128 100a
Negative (37) 0.5–128 128 22
Ceftazidime-clavulanateb Positive (53) 0.12–128 128 68c
Negative (37) 0.12–128 128 41c
Cefepime Positive (53) 64–128 128 100
Negative (37) 0.12–128 32 30
a All of the blaPER-1-positive isolates were also resistant to cefotaxime and
aztreonam.
b Fixed concentration of 4 g of clavulanate/ml.
c Breakpoint for ceftazidime was applied.
d MIC90, MIC at which 90% of the isolates tested are inhibited.
TABLE 2. Phenotypic differentiation of 51 PER-1-producing
isolates by cefepime disk and -lactamase inhibitor-
supplemented cefepime disk
Inhibitor added to
a cefepime disk
No. (%) of isolates with zone
diam difference ofa:
5 mm 5 mm
Clavulanate, 10 g 42 (82.4) 9 (17.6)
Clavulanate, 20 g 50 (98.0)b 1 (2.0)
Tazobactam, 10 g 39 (76.5) 12 (23.5)
Tazobactam, 20 g 51 (100) 0 (0)
a Difference in zone diameter between a cefepime disk and a cefepime disk
plus inhibitor.
b Mean inhibition zone diameter difference between cefepime and cefepime
plus 20 g of clavulanate was only 6.7 mm.
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a difference of 5 mm was arbitrarily defined as positive (Ta-
ble 2). More positive isolates were detected with a cefepime
disk containing 20-g than 10-g inhibitors, but the zone size
differences remained small for both inhibitors. Therefore, PCR
is considered the more reliable method for detecting blaPER-1-
producing Acinetobacter spp. This is the first report of high
prevalence of blaPER-1-positive acinetobacters outside Europe
and indicates possible presence of the resistance in other coun-
tries.
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